Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Short term Debt (2016 - 2024)

Historic Short term Debt for BioCorRx (BICX) over the last 8 years, with Q3 2024 value amounting to $1.2 million.

  • BioCorRx's Short term Debt changed N/A to $1.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.2 million, marking a year-over-year change of. This contributed to the annual value of $999088.0 for FY2023, which is N/A changed from last year.
  • Per BioCorRx's latest filing, its Short term Debt stood at $1.2 million for Q3 2024.
  • In the past 5 years, BioCorRx's Short term Debt ranged from a high of $3.1 million in Q2 2022 and a low of $31580.0 during Q4 2021
  • Its 5-year average for Short term Debt is $1.8 million, with a median of $2.3 million in 2020.
  • Its Short term Debt has fluctuated over the past 5 years, first soared by 2516.81% in 2020, then tumbled by 9867.89% in 2021.
  • Quarter analysis of 5 years shows BioCorRx's Short term Debt stood at $2.4 million in 2020, then tumbled by 98.68% to $31580.0 in 2021, then skyrocketed by 9721.92% to $3.1 million in 2022, then crashed by 67.79% to $999088.0 in 2023, then rose by 21.61% to $1.2 million in 2024.
  • Its Short term Debt was $1.2 million in Q3 2024, compared to $865353.0 in Q2 2024 and $80190.0 in Q1 2024.